News Releases

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...

-TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic- -Conference call and webcast today, Nov. 29th, at 9:00 am ET- CARLSBAD, Calif., Nov. 29, 2022 /PRNewswire/ -- Tyra...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...

-Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as of Q3 2022- CARLSBAD,...

-Esther van den Boom to transition to an advisor at year-end 2022- -Alan Fuhrman to be named Chief Financial Officer- CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today...

-IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1...

-Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARLSBAD, Calif., May 5, 2022 /PRNewswire/...